Background: HBV DNA and quantitative (q)HBsAg levels as prognostic markers for
Current anti-viral strategies are cost-intensive long-term treatments with potential side effects and patients who benefit must be cautiously identified. [3] [4] [5] [6] However, patients with HBeAg-negative chronic HBV infection, not fulfilling treatment criteria, must also be followed for the long term because they are still at risk of disease progression and HBV-related complications. Therefore, recent research efforts aimed at developing prognostic markers for disease progression. Mutations in the basal core promotor (BCP A1762T/ G1764A) and in the precore (PC) region (G1896A and G1896A/ G1899A) are associated with HBeAg negativity and together with mutations in preS (deletions and start codon mutations) they have been described as prognostic markers for disease progression and disease-related complications but have not been established in daily clinical practice so far. [7] [8] [9] [10] In contrast, HBV DNA levels above 2000 IU/mL and quantitative (q)HBsAg levels above 1000 IU/mL were found to be associated with liver disease progression and development of hepatocellular carcinoma and have become an integral part of clinical HBV disease assessment. [11] [12] [13] [14] [15] Importantly, these markers and cut-offs were developed and vali- HBsAg in the endoplasmic reticulum in vitro. 16 Also genotypedependent differences in the amount of secreted virion DNA were observed in another in vitro study. 17 However, comprehensive in vivo studies analysing the genotype-specific impact on HBV DNA and qHBsAg levels in specific phases of HBV infection are missing.
While an influence of BCP and PC mutations on viral replication was observed in some in vitro studies, the molecular virological impact of preS mutations was predominantly studied in the context of hepatocarcinogenesis. 2 Clinically, a genotype-dependent prevalence was described for BCP and PC mutations among genotypes A-D and for preS mutations among genotypes B and C, respectively, 18 but only few data are available discussing their prevalence in the other genotypes. In addition, the influence of these mutations on HBV DNA and qHBsAg levels is largely unknown.
In this study, we analysed the impact of genetically different with HBeAg-negative chronic HBV infection (HBeAg-negative, normal transaminases, HBV DNA <20000 IU/mL) were included in the analysis. For main inclusion and exclusion criteria of the Albatros trial, see supporting information. Serum or plasma of these patients was prospectively collected and stored at À80°C.
Analyses of HBV DNA viral load and qHBsAg were limited to patients with available HBV DNA and qHBsAg levels at baseline (n = 465; 100% and n = 433; 93%, respectively), which were determined in clinical routine. HBV genotypes were either determined in clinical routine or during the present study analysis by direct sequencing of the polymerase region.
The study was approved by local ethics committees and written informed consent was obtained from all patients. The study was performed in accordance with the provisions of the Declaration of Helsinki and good clinical practice guidelines.
| DNA extraction
Viral DNA was extracted from 200 lL of serum using the QIAamp DNA Blood Mini Kit (Qiagen, Germany) and QIAamp UltraSens Virus Kit (Qiagen, Germany) according to the manufacturer's protocol.
| Primers
Primers are described in the supporting information. 
| Amplification of the full-length HBV genome
The entire HBV genome was amplified with modified primers P1 and P2 from G€ unther et al. 19 The Expand High Fidelity PCR Kit (Roche, Germany) was used and the cycling conditions are described in the supporting information. Table 1 ). However, HBV genotypes B (GTB: 7%; 34/465), E (GTE: 3.2 | Precore G1896A AE G1899A is associated with higher and BCP A1762T/G1764A is associated with lower HBV DNA levels No significant differences in HBV DNA serum levels were detected among the different HBV genotypes ( Figure 2A ). For subgenotypes A1 and A2, no significant differences in HBV DNA serum levels were observed (data not shown). Significant higher HBV DNA levels were observed in patients who harboured the precore G1896A single mutation or the precore G1896A/G1899A double mutation in comparison to patients without these mutations (3.0 log IU/mL vs 2.6 log IU/mL; P < 0.001) ( Figure 2B ). In contrast, patients with the BCP A1762T/G1764A mutation showed significantly lower HBV DNA levels compared to patients without this double mutation (2.6 log IU/mL vs 3.0 log IU/mL; P < 0.001) ( Figure 2B ). Patients harbouring the BCP A1762T/G1764A plus the precore G1896A single mutation or the precore G1896A/G1899A double mutation had significantly higher HBV DNA levels compared to patients without any of those combinations (3.1 log IU/mL vs 2.8 log IU/mL; P = 0.001; data not shown). In patients with or without deletions or mutations in the preS domain, similar viral loads were observed (2.9 log IU/mL vs 2.8 log IU/mL; P = 0.551) ( Figure 2B ). Recently also, 2 newly described mutations in precore (C1817T and A1838G)
were associated with very low baseline HBV DNA levels. 25 In our study cohort, these mutations were found only infrequently (5/465 patients with C1817T and 2/465 patients with A1838G).
| qHBsAg levels vary between HBV genotypes
and are associated with mutations in precore and preS
Quantitative HBsAg serum levels varied significantly among HBV genotypes. While the highest qHBsAg levels were found in patients infected with GTA (3.9 log IU/mL, irrespective of the subgenotype) and GTE (3.7 log IU/mL), significantly lower levels were detected in patients infected with GTB (2.5 log IU/mL; P < 0.001) ( Figure 2C ).
qHBsAg levels were also significantly higher in GTA vs GTD (3.1 log IU/mL, P < 0.001) and in GTC (3.6 log IU/mL) and GTD (3.1 log IU/mL) as compared to GTB (P = 0.01 and P = 0.01, respectively).
Regarding the widely used HBsAg cut-off of 1000 IU/mL as a prognostic marker, only 13% (3/23) of GTE and 18% (19/105) of GTA-infected patients had qHBsAg levels <1000 IU/mL, whereas significantly more GTD-(49%; 124/252) and GTB-(68%; 23/34) infected patients had qHBsAg levels <1000 IU/mL ( Figure 2E ).
Quantitative HBsAg levels also varied in patients with different mutations. Patients with precore single mutation G1896A or double mutation G1896A/G1899A had a significant lower amount of T A B L E 1 Epidemiological, virological and serological characteristics of HBeAg-negative patients infected chronically with HBV Parameter Total, n (%) GTA, n (%) GTB, n (%) GTC, n (%) GTD, n (%) GTE, n (%) qHBsAg (3.1 log IU/mL vs 3.3 log IU/mL; P = 0.001) in comparison to patients without those mutations ( Figure 2D ). Patients who harboured a preS deletion or preS2 start codon mutation had a significantly higher amount of qHBsAg (3.7 log IU/mL vs 3.2 log IU/mL; P < 0.001) ( Figure 2D ). Deletions in the preS1 or the preS2 domain were associated with higher qHBsAg (3.6 log IU/mL and 3.8 log IU/mL vs 3.2 log IU/mL, respectively; P = 0.03 and P = 0.001, respectively, data not shown). However, no association of qHBsAg levels and the BCP A1762T/G1764A double mutation was found in our study cohort (3.3 log IU/mL vs 3.2 log IU/mL; P = 0.65) ( Figure 2D ). Also in patients with BCP A1762T/G1764A plus precore G1896A single mutation or precore G1896A/G1899A double mutation, no association with qHBsAg levels could be detected (3.0 log IU/mL vs 3.2 log IU/mL; P = 0.123; data not shown). GTB GTC GTD GTE GTA GTB GTC GTD GTE among genotypes B and C, respectively. 2 As no data are published regarding the prevalence of these mutations in HBV genotype E 18 , we found that the vast majority of GTE-infected patients harboured the BCP double mutation. While preS mutations were also commonly found, mutations in precore were detected only infrequently in this genotype. In line with other studies, the BCP double mutation A1762T/G1764A was found with a high frequency in HBV genotype C, and mutations in PC were detected frequently in genotypes B, C and D but only infrequently in HBV genotype A. Deletions in preS and preS2-start codon mutations were found also in line with other studies with the highest frequency in GTC.
2,27
Interestingly, we found that although the genotype influences viral replication in vitro, 17 the HBV genotype is not associated with HBV DNA serum levels in patients with HBeAg-negative HBV infection. In contrast, we observed that PC mutations are associated with significantly higher HBV DNA levels and BCP mutations are associated with lower HBV DNA levels, respectively. In in vitro studies, a replication enhancing effect of PC mutations had been shown, 17, 28 which could also be confirmed in our in vitro analysis.
Interestingly, in spite of an enhanced replication extracellular HBV DNA amounts were found to be lower in this variant, which is in line with another in vitro study. 29 However, patients with HBeAgnegative chronic HBV infection and PC mutations have higher HBV DNA levels as observed in our study cohort. Therefore, our in vivo | 1533
Importantly, we found that quantitative HBsAg serum levels vary significantly (2.5 -3.9) among HBV genotypes in our patients with HBeAg-negative chronic HBV infection. This is in line with a recent Spanish study including 135 patients with HBeAg-negative chronic HBV infection and 67 patients with chronic hepatitis B. 30 Interestingly, when applying the qHBsAg cut-off <1000 IU/mL which has been associated with a favourable disease course and which has also been implemented in the recent EASL guideline for monitoring these patients, 3 significant differences were observed between the different genotypes. While only a low percentage of HBV genotype Eand A-infected patients had qHBsAg levels <1000 IU/mL, the majority of GTB-infected patients had levels below this cut-off. As this cut-off was developed to differentiate between inactive carriers and patients who are at risk for reactivation and disease progression 13, 15 our findings may implicate that patients infected with HBV genotypes A and E are at higher risk of disease progression, which has not been reported in the literature so far. We believe that these striking differences in qHBsAg levels may be due to a genotypedependent efficacy of HBsAg expression and/or release, which has also been observed in 2 in vitro studies. 17, 21 Importantly, qHBsAg cut-offs (ie 1000 IU/mL) have been developed for several clinical situations to determine the individual risks of HBV-infected patients.
Cut-offs were validated to discriminate between active and inactive carriers, 13, 14 as prognostic factors for the risk of HCC development 15, 31 and for predicting treatment response to therapy with pegylated interferon and with nucleos(t)ide analogues. 32, 33 However, based on our data, the use of qHBsAg cut-offs as a prognostic marker for disease progression should undergo HBV genotype-dependent validation.
In addition, we found significantly higher qHBsAg levels in patients with preS mutations, whereas another smaller study including 14
HBeAg-positive and negative patients with preS or S mutations observed lower HBsAg levels in these patients with mutations. 34 While we found lower qHBsAg levels in patients with PC mutations, in our in vitro analysis a diminishing impact of PC variants on HBsAg expression and release could not be observed, which is in line with a recent study from Australia. 17 In contrast, we found that preS-del. observed. 16 Therefore, HBsAg release seems to be diminished in all our analysed genomes, which are derived from patients with HBeAgnegative chronic HBV infection except for the preS-del.-variant. This may indicate that generally lower qHBsAg serum levels that are commonly observed in patients of this disease phase 3 may be partly caused by a lower HBsAg release.
In conclusion, the HBV genotype does not influence HBV DNA serum levels but is highly significant associated with qHBsAg levels in patients infected with HBeAg-negative chronic HBV infection.
Therefore, qHBsAg cut-offs when used as prognostic markers require genotype-dependent validation. In addition, frequent mutations in precore, basal core promoter and preS are found in a genotype-dependent pattern and they have an impact on HBV DNA and qHBsAg serum levels in vivo and in vitro. Our in vitro data suggest that low HBsAg levels in patients with a HBeAg-negative HBV infection might be caused by a diminished HBsAg secretion.
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